ATON - PORTAGE BIOTECH INC.

0.366
-0.027   -7.377%

Share volume: 493,782
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$0.39
-0.03
-0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
-6.54%
1 Month
-28.52%
3 Months
-79.20%
6 Months
-93.79%
1 Year
-91.78%
2 Year
-33.47%
Key data
Stock price
$0.37
P/E Ratio 
0.00
DAY RANGE
$0.36 - $0.39
EPS 
N/A
52 WEEK RANGE
$0.35 - $15.82
52 WEEK CHANGE
-$90.85
MARKET CAP 
3.618 M
YIELD 
N/A
SHARES OUTSTANDING 
1.049 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
1.56
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$480,918
AVERAGE 30 VOLUME 
$696,222
Company detail
CEO: Ian B. Walters
Region: US
Website: portagebiotech.com
Employees: 6
IPO year: 2007
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Portage Biotech Inc. researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology.

Recent news